Impurities Workshop Part III - Elemental Impurities
Im Auftrag der ECA Academy
Heidelberg, Germany
Seminar Nr. 17867
Unser Seminarservice
Kosten
| ECA-Member: | EUR 890,-- |
| Non ECA Member: | EUR 1090,-- |
| EU/GMP Inspectorates: | EUR 545,-- |
| APIC Member Discount: | EUR 990,-- |
Alle Preise zzgl. MwSt.
Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail: info@concept-heidelberg.de
Sprecher
Dr Ulrich Rose, EDQM, France
Jürgen Martin, Martin-Consulting, Germany
Dr Andrew Teasdale, AstraZeneca, UK
Jürgen Martin, Martin-Consulting, Germany
Dr Andrew Teasdale, AstraZeneca, UK
Zielsetzung
In Part III of the Impurities Workshop the key principles of the ICH Q3D Guideline on elemental impurities will be highlighted. You will get to know the essential aspects and approaches of how to assess the risks and control elemental impurities in drug substances, drug products and excipients.
You will learn
You will learn
- what has to be considered with respect to the drug substance monographs of the European Pharmacopoeia,
- how to perform a risk assessment in order to establish a control strategy for elemental impurities,
- how the route of administration and the duration of exposure affect the limits of elemental impurities,
- which potential sources of Elemental Impurities within the supply chain you have to be aware of.
Hintergrund
In November 2014 the ICH Q3D Guideline for Elemental Impurities was published as Step 4 document. This document outlines
- the evaluation of the toxicity data for potential elemental impurities
- the PDEs for each element of toxicological concern
- the basis for an EI risk assessment and the key factors for evaluation.
- the development of controls designed to limit the inclusion of elemental impurities in drug products to levels at or below the PDE
Meanwhile ICH Q3D was revised twice, regarding Cadmium Inhalation PDE (ICH Q3D(R1); Step 2 document) and cutaneous and transdermal products (ICH Q3D(R2); Concept Paper)
Zielgruppe
The conference addresses all personnel involved in development of drug substances and drug products from scientific staff to laboratory heads involved in R&D. The needs of Laboratory Managers, Supervisors and Analysts in pharmaceutical quality assurance and quality control departments will also be covered.
Programm
European Pharmacopoeia Activities (Policy) on Elemental Impurities – an Update
- Implementation of Q3D in Ph. Eur.
- Changes in individual and general monographs
- Harmonisation of general chapter 2.4.20
- Second phase for revision of excipient monographs
Risk-Based Approach for Elemental Impurities in the Supply Chain
- APIs, excipients, packaging materials impacting the purity profile
- Evaluation of supply chain processes
- Risk analysis as evaluation tool
- Audits- and monitoring programs as important sources
- Testing strategies
Control Strategies for Elemental Impurities in Final Dosage Forms – Case Studies
- Utilisation of Data as part of an Integrated EI Risk Assessment Process
- Potential Sources of Elemental Impurities in the Finished Product
- API
- Equipment
- Container-closure system
- Excipients
- Conclusions
Workshop:
Conducting a Risk Assessment
Conducting a Risk Assessment
In this Workshop the participants will work on several case studies and perform a risk assessment for different scenarios taking into account e.g. manufacturing equipment, dosage form of the drug product etc.
GMP Seminare nach Thema
- Qualitätssicherung / Dokumentation
- Regulatory Affairs and Compliance
- Entwicklung / Prüfpräparate
- Datenintegrität
- Qualitätskontrolle / Analytik / Statistik
- GDP - Lager - Logistik
- Computervalidierung
- Validierung / Qualifizierung
- GMP in Produktion / Technik
- GMP für Wirkststoffe und Hilfsstoffe
- Medizinprodukte und Kosmetika
- GMP Basisausbildung
- Packmittel / Verpackung
- Hygiene / Mikrobiologie / Steril
- Biotechnologie
- Einkauf / Betriebswirtschaft / Effizienz
- European Conferences and Education Courses
- Sonstige Themen